Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Medpace's financial results for the first quarter of 2023 highlight a mixed scenario, reflecting both the opportunities and challenges inherent in the clinical contract research organization (CRO) industry.</li><li>The company reported that revenues reached $511 million for the quarter, marking a significant 17.7% increase on a year-over year basis.</li><li>This positive trajectory can be attributed to healthy demand for Medpace’s clinical research services, as demonstrated by the growth in ending backlog which stood at approximately $2.9 billion—an increase of 18.2% compared to the previous year.</li></ul>

Medpace's financial results for the first quarter of 2023 highlight a mixed scenario, reflecting both the opportunities and challenges inherent in the clinical contract research organization (CRO) industry.The company reported that revenues reached $511 million for the quarter, marking a significant 17.7% increase on a year-over year basis.This positive trajectory can be attributed to healthy demand for Medpace’s clinical research services, as demonstrated by the growth in ending backlog which stood at approximately $2.9 billion—an increase of 18.2% compared to the previous year.

Medpace Holdings Inc.: Will The Improved Bookings Environment Last? - Major Drivers

<ul><li>Medpace Holdings, a leading full-service clinical contract research organization (CRO), reported robust results for the fourth quarter and full year of 2023.</li><li>The company's revenue increased 26.5% year-over-year in Q4, reaching $498.4 million.</li><li>For the full year, revenue stood at $1.89 billion, a rise of 29.2% from 2022.</li></ul>

Medpace Holdings, a leading full-service clinical contract research organization (CRO), reported robust results for the fourth quarter and full year of 2023.The company's revenue increased 26.5% year-over-year in Q4, reaching $498.4 million.For the full year, revenue stood at $1.89 billion, a rise of 29.2% from 2022.

Medpace Holdings Inc.: Initiation Of Coverage - Does It Have A Sustainable Competitive Advantage? - Major Drivers

European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>The 1,350p offer for <a href="https://www.smartkarma.com/entities/ergomed-plc" target="_blank" data-smartkarma-citation="entities:23411:1" rel="noopener">Ergomed Plc (ERGO LN)</a> (28% premium, 18.9x EV/Fwd NTM EBITDA using IBES estimated) seems optically attractive considering share underperformance, and in line with closest peer Medpace at 19.06x.</li>
<li>Nevertheless there'd be synergies available to a trade buyer and other than 18% from the Founder, there aren't any other irrevocables, which indicates the offer price is far from knock-out.</li>
<li>I set my TP at 1,350p. Spread turned negative last week, now 0.59%/1.71% (gross/annualised, assuming settlement by mid-February). I would be long considering there's still time for a competing offer.</li>
</ul>


The 1,350p offer for Ergomed Plc (ERGO LN) (28% premium, 18.9x EV/Fwd NTM EBITDA using IBES estimated) seems optically attractive considering share underperformance, and in line with closest peer Medpace at 19.06x.
Nevertheless there'd be synergies available to a trade buyer and other than 18% from the Founder, there aren't any other irrevocables, which indicates the offer price is far from knock-out.
I set my TP at 1,350p. Spread turned negative last week, now 0.59%/1.71% (gross/annualised, assuming settlement by mid-February). I would be long considering there's still time for a competing offer.


IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Frontage Holdings / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/27754" target="_blank" data-smartkarma-citation="entities:27754:1">Frontage Holdings (1521 HK)</a> has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200 million). Three cornerstone investors, Hillhouse Capital, Greenwoods Asset Management and OrbiMed Advisors, intend to purchase $90 million of the offering.</p><div class="content-highlight"><p>In <a href="https://www.smartkarma.com/insights/frontage-holdings-ipo-preview-an-uncertain-transition" target="_blank">our IPO initiation note</a>, we cautioned that while the market backdrop is favourable, Frontage is a business in the middle of an uncertain transition. Overall, with the caveat that Frontage has yet to prove that it can reaccelerate organic revenue growth, we believe that the risk-reward profile is favourable at the low-end of IPO price range. </p></div>

Frontage Holdings (1521 HK) has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200 million). Three cornerstone investors, Hillhouse Capital, Greenwoods Asset Management and OrbiMed Advisors, intend to purchase $90 million of the offering.In our IPO initiation note, we cautioned that while the market backdrop is favourable, Frontage is a business in the middle of an uncertain transition. Overall, with the caveat that Frontage has yet to prove that it can reaccelerate organic revenue growth, we believe that the risk-reward profile is favourable at the low-end of IPO price range. 

Frontage Holdings IPO: Risk-Reward Is Favourable at the Low-End of Price Range

<p><a href="https://www.smartkarma.com/entities/27850" target="_blank" data-smartkarma-citation="entities:27850:1">Viva Biotech Holdings (1873 HK)</a> is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232 million ($157 million), at the mid-point of the IPO price range.</p><div class="content-highlight"><p>Overall, with the caveat that Viva's valuation is highly dependent on fair value gains (from its portfolio companies), we believe that Viva can just about justify the low-end of IPO price range</p></div>

Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232 million ($157 million), at the mid-point of the IPO price range.Overall, with the caveat that Viva's valuation is highly dependent on fair value gains (from its portfolio companies), we believe that Viva can just about justify the low-end of IPO price range

Viva Biotech IPO: Just About Supporting the Low-End IPO Price Range

United States

Medpace Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides cardiovascular, hematology, oncology, neurology, pediatrics, nephrology, and diagnostic services. Medpace Holdings serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medpace Holdings Inc (MEDP US)

Medpace Holdings Inc.: Will The Improved Bookings Environment Last? - Major Drivers

Medpace's financial results for the first quarter of 2023 highlight a mixed scenario, reflecting both the opportunities and challenges inherent in...

Baptista Research

Medpace Holdings Inc.: Initiation Of Coverage - Does It Have A Sustainable Competitive Advantage? - Major Drivers

Medpace Holdings, a leading full-service clinical contract research organization (CRO), reported robust results for the fourth quarter and full...

Baptista Research

No Danger in Being Long

Spread turned negative and widened in the last week. I believe the risk/reward of adding at or below 1,340p is more favourable considering that...

Jesus Rodriguez Aguilar

Frontage Holdings IPO: Risk-Reward Is Favourable at the Low-End of Price Range

Frontage Holdings (1521 HK) has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200...

Arun George

Viva Biotech IPO: Just About Supporting the Low-End IPO Price Range

Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)